Researchers are appealing for cancer survivors to help with an AI-based project aimed at developing new immunotherapies.
Scientists from the University of Surrey are working with the biotech company Etcembly on the project, which aims to find clues in the immune systems of long-term survivors that may help to improve immunotherapy in the future.
The project will use large language models and advanced structural modelling to study T-cells and identify the molecules they target within cancer cells. The researchers hope they can identify new targets within 18 months, hoping to develop a “new generation” of immunotherapies.
Etcembly will be using single cell sequencing technology and an AI-driven analytical platform developed by the company, enabling the study of “millions” of T-cell receptors and antibodies.
Professor Hardev Pandha, professor of medical oncology at the University of Surrey, said: “Immunotherapy has been transformational in the field of oncology this last decade.
“Studying the immune system, and in particular the tumour immune microenvironment, in these responder patients using Etcembly’s approach will be strongly supported by patients to accelerate the development of potent immunotherapies applicable to a wide range of cancers.”
Source: Etcembly
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News.